AstraZeneca -- Physician Payments Report
This page provides a comprehensive analysis of AstraZeneca's payments to physicians, as reported in the CMS Open Payments (Sunshine Act) database. DoctorPharmaData enhances this data with AI-powered analysis to help patients understand pharmaceutical company spending patterns.
Spending Summary
AstraZeneca has made $8,635,838.71 in total payments to 0 physicians across 815 recorded transactions.
- Total Physician Spending: $8,635,838.71
- Total Physicians Paid: 0
- Total Payment Transactions: 815
Recent Payment Records
The following table shows the most recent payments from AstraZeneca to physicians as recorded in the CMS Open Payments database.
| Doctor | Specialty | Amount | Type | Date |
|---|---|---|---|---|
| Jeffrey Campbell | Nephrology | $96.54 | meals | 2026-04-07 |
| Timothy Rogers | Endocrinology | $85.66 | meals | 2026-04-04 |
| Angela Stewart | Pulmonology | $25,196.05 | consulting | 2026-03-31 |
| Sarah Chen | Endocrinology | $2,869.07 | consulting | 2026-03-31 |
| Karen Harris | Oncology | $4,780.15 | travel | 2026-03-27 |
| Paul Turner | Cardiology | $23,263.22 | consulting | 2026-03-26 |
| Amy Phillips | Endocrinology | $123.42 | meals | 2026-03-26 |
| David Kim | Pulmonology | $14,829.70 | consulting | 2026-03-26 |
| Michael Rodriguez | Pulmonology | $3,456.33 | travel | 2026-03-23 |
| Melissa Reed | Pulmonology | $197.42 | general | 2026-03-21 |
| Kevin Hill | Nephrology | $7,334.80 | consulting | 2026-03-20 |
| Amy Phillips | Pulmonology | $12,790.28 | consulting | 2026-03-19 |
| Matthew Walker | Endocrinology | $8,549.74 | speaking | 2026-03-18 |
| Daniel White | Pulmonology | $25.82 | meals | 2026-03-15 |
| Amanda Lewis | Oncology | $10,348.48 | consulting | 2026-03-15 |
Understanding Pharmaceutical Company Payment Reports
Under the Physician Payments Sunshine Act, pharmaceutical and medical device companies must report all payments and transfers of value to licensed physicians and teaching hospitals. AstraZeneca is required to disclose every payment, including consulting fees, speaking engagements, meals, travel, research funding, and ownership interests.
A high spending total does not necessarily indicate improper behavior. Large pharmaceutical companies with extensive product portfolios naturally make more payments to physicians. However, examining the patterns of spending -- which specialties are targeted, which doctors receive the most, and what types of payments predominate -- can provide valuable insights for patients.
Related Resources
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice.